2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1632

Identification Of a Novel Systemic Lupus Erythematosus Risk Locus Between FCHSD2 and P2RY2 In Koreans
Abstract Number: 2772

Identification Of a Sjögren’s Syndrome-Associated Variant That Influences OAS1 Isoform Switching
Abstract Number: 1895

Identification Of Aberrant Pathways In Osteoarthritis Using RNA-Seq
Abstract Number: 2063

Identification Of Autoantibodies To Tyrosyl–Transfer RNA Synthetase Associated With Anti-Synthetase Syndrome
Abstract Number: 154

Identification Of Autoimmune Disease Genes In Regions Under Selection In The Gullah African American Population Of South Carolina
Abstract Number: 153

Identification Of Autoimmune Disease Risk Alleles That Are Under Recent Selection In The Sea Island Gullah African Americans
Abstract Number: 2171

Identification Of Best Cutoff Points and Clinical Signs Specific For Early Recognition Of Macrophage Activation Syndrome In Active Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2085

Identification Of Clinical Features and Risk Factors Associated With Calcinosis In Adult Patients With Dermatomyositis
Abstract Number: 2453

Identification Of Determinants Of The Functional Outcome In Patients With Early Axial Spondyloarthritis: Results From The German Spondyloarthritis Inception Cohort
Abstract Number: 1712

Identification Of Factors Associated With Agreement Between Rheumatoid Arthritis Electronic Medication Lists and Prescribed Disease Modifying Treatment Plans
Abstract Number: 2697

Identification Of Genetic and Epigenetic Alterations In Spondyloarthritis
Abstract Number: 519

Identification Of IgG4-Related Disease and Analysis Of IgG4 Serum Levels In Different Subgroups Of Patients With Sjögren’s Syndrome
Abstract Number: 2799

Identification Of IL-10 Producing Plasma Cells In Human and Its Deficiency In Systemic Lupus Erythematosus Patients
Abstract Number: 176

Identification Of Major Histocompatibility Complex Class II Alleles Associated With Systemic Sclerosis Through Imputation Strategy
Abstract Number: 1702

Identification of Multiple Genetic Susceptibility Loci in Takayasu’s Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].